Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?
Executive Summary
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.